In this large cohort study, patients with PA treated with MR antagonists had 2–3 times higher risk for incident cardiovascular events and death, when compared to age-matched essential hypertensives, even though they had similarly controlled (and relatively normalized) blood pressure while on MR antagonist therapy [19]. Here, NR3C2 is linked to hypertensive disorder.